GlaxoSmithKline said Monday data from a phase 3b study showed biologic Nucala consistently improved health-related quality of life and lung function in patients with severe asthma. ADRs drifted slightly lower intraday. Data from the post-hoc analysis of the MUSCA study, which was presented at the American Thoracic Society conference in Washington DC, looked at treatment response in week 24 from patients treated with mepolizumab compared to placebo.
The results showed an improvement in both quality of life and lung function versus placebo, the company said in a statement. MUSCA is the first study designed to primarily assess the effect of mepolizumab on the patient’s quality of life, while lung function was the first secondary endpoint. This “post-hoc analysis shows Nucala has the potential to offer meaningful improvements in important clinical endpoints, as well as patient-reported outcomes, in severe asthma patients with blood eosinophil levels of 150 cells/mL and above,” said Frank Albers, global medical affairs lead for Nucala at GlaxoSmithKline.